BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
Q3 FY21 is expected to have been a good quarter for Indian pharma companies. Some of the benefits from H1 FY21 are expected to have boosted growth.
Sales of the companies we cover are expected to have risen 9.2% to Rs 157 billion, driven by a strong rebound in India sales, greater demand for active pharmaceutical ingredients and stable pricing in the U.S.
Ebitda margins may be high due to less promotional and travelling expense associated with the domestic business.
We expect Ebitda margins of companies we cover to have expanded 180 basis points to 24.4% (27.6% the quarter prior).
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR